Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF
Circulation · 30.05.2023 · 147 (22) · 1670-1683
DOI: 10.1161/circulationaha.122.063327 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 30.05.2023. Verfasst von Su Ern Yeoh und 19 weiteren Autor:innen. Beteiligte Einrichtung: British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (S.E.Y., K.F.D., R.T.C., P.S.J., N.S., P.W., J.J.V.M.). Hauptthemen laut MEDLINE: Heart Failure, Ventricular Dysfunction, Left. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
ET-1 (endothelin-1) is implicated in the pathophysiology of heart failure and renal disease. Its prognostic importance and relationship with kidney function in patients with heart failure with reduced ejection fraction receiving contemporary treatment are uncertain. We investigated these and the efficacy of dapagliflozin according to ET-1 level in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure).
Methods
We investigated the incidence of the primary outcome (cardiovascular death or worsening heart failure), change in kidney function, and the effect of dapagliflozin according to baseline ET-1 concentration, adjusting in Cox models for other recognized prognostic variables in heart failure including NT-proBNP (N-terminal pro-B-type natriuretic peptide). We also examined the effect of dapagliflozin on ET-1 level.
Results
Overall, 3048 participants had baseline ET-1 measurements: tertile 1 (T1; ≤3.28 pg/mL; n=1016); T2 (>3.28–4.41 pg/mL; n=1022); and T3 (>4.41 pg/mL; n=1010). Patients with higher ET-1 were more likely male, more likely obese, and had lower left ventricular ejection fraction, lower estimated glomerular filtration rate, worse functional status, and higher NT-proBNP and hs-TnT (high-sensitivity troponin-T). In the adjusted Cox models, higher baseline ET-1 was independently associated with worse outcomes and steeper decline in kidney function (adjusted hazard ratio for primary outcome of 1.95 [95% CI, 1.53–2.50] for T3 and 1.36 [95% CI, 1.06–1.75] for T2; both versus T1; estimated glomerular filtration rate slope: T3, –3.19 [95% CI, –3.66 to –2.72] mL/min per 1.73 m 2 per y, T2, –2.08 [95% CI, –2.52 to –1.63] and T1 –2.35 [95% CI, –2.79 to –1.91]; P =0.002). The benefit of dapagliflozin was consistent regardless of baseline ET-1, and the placebo-corrected decrease in ET-1 with dapagliflozin was 0.13 pg/mL (95% CI, 0.25–0.01; P =0.029).
Conclusions
Higher baseline ET-1 concentration was independently associated with worse clinical outcomes and more rapid decline in kidney function. The benefit of dapagliflozin was consistent across the range of ET-1 concentrations measured, and treatment with dapagliflozin led to a small decrease in serum ET-1 concentration. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03036124.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (S.E.Y., K.F.D., R.T.C., P.S.J., N.S., P.W., J.J.V.M.).
- BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (A.H., M.S., O.B., P.J.G.).
- Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, The Netherlands (H.J.L.H.).
- George Institute for Global Health, University of New South Wales, Sydney, Australia (H.J.L.H.).
- Department of Pathology (P.J.), Brigham and Women's Hospital, Boston, MA.
- Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Denmark (L.K.).
ORCID-Profile: Kieran F Docherty, Pardeep S Jhund, Hiddo J L Heerspink, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Scott D Solomon, Mikaela Sjöstrand, Olof Bengtsson, Naveed Sattar, Paul Welsh, Marc S Sabatine, David A Morrow, John J V McMurray
Förderung
- British Heart Foundation
Zitieren
APA
Yeoh, S. E., Docherty, K. F., Campbell, R. T., Jhund, P. S., Hammarstedt, A., Heerspink, H. J. L., Jarolim, P., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Solomon, S. D., Sjöstrand, M., Bengtsson, O., Greasley, P. J., Sattar, N., Welsh, P., Sabatine, M. S., Morrow, D. A., & McMurray, J. J. V. (2023). Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF. Circulation, 147(22), 1670-1683. https://doi.org/10.1161/circulationaha.122.063327
Vancouver
Yeoh SE, Docherty KF, Campbell RT, Jhund PS, Hammarstedt A, Heerspink HJL, et al. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF. Circulation. 2023;147(22):1670-1683. doi:10.1161/circulationaha.122.063327
BibTeX
@article{Yeoh2023,
author = {Yeoh, Su Ern and Docherty, Kieran F and Campbell, Ross T and Jhund, Pardeep S and Hammarstedt, Ann and Heerspink, Hiddo J L and Jarolim, Petr and Køber, Lars and Kosiborod, Mikhail N and Martinez, Felipe A and Ponikowski, Piotr and Solomon, Scott D and Sjöstrand, Mikaela and Bengtsson, Olof and Greasley, Peter J and Sattar, Naveed and Welsh, Paul and Sabatine, Marc S and Morrow, David A and McMurray, John J V},
title = {Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF},
journal = {Circulation},
year = {2023},
volume = {147},
number = {22},
pages = {1670--1683},
doi = {10.1161/circulationaha.122.063327}
}
EUVIMED